- Conditions
- Non Small Cell Lung Carcinoma NSCLC
- Interventions
- Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 953 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 15
- States / cities
- Anaheim, California • San Diego, California • Santa Rosa, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 767
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19
- Interventions
- Favipiravir, Standard of Care
- Drug · Other
- Lead sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Miami, Florida • Boston, Massachusetts + 3 more
- Conditions
- Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Interventions
- NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • St Louis, Missouri
- Conditions
- Hypoplastic Left Heart Syndrome
- Interventions
- c-kit+ cells
- Biological
- Lead sponsor
- Joshua M Hare
- Other
- Eligibility
- 1 Day to 21 Days
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 1 more
- Conditions
- Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
- Interventions
- VS-01 on top of SOC (Active Treatment Group), SOC
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Knee Osteoarthritis
- Interventions
- Embosphere Microspheres
- Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Diabetic Macular Edema
- Interventions
- Standard of Care Group, 1mg triamcinolone acetonide, 4mg triamcinolone acetonide
- Procedure · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 84
- States / cities
- Little Rock, Arkansas • Baldwin Park, California • Beverly Hills, California + 67 more
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
- Combination Product · Biological · Drug
- Lead sponsor
- Rakuten Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Duarte, California • Miami, Florida • Tampa, Florida + 5 more
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Spine
- Interventions
- Immunotherapy, Stereotactic Radiosurgery, Vertebroplasty
- Other · Radiation · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Rozibafusp Alfa, Placebo for Rozibafusp Alfa
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Covina, California + 31 more
- Conditions
- Joint Infection
- Interventions
- No-Rinse Solution (NS), Saline irrigation
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- Not listed
- Enrollment
- 936 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Manhasset, New York • New Hyde Park, New York • New York, New York
- Conditions
- Advanced or Metastatic Colorectal Cancer
- Interventions
- Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
- Interventions
- LY3537021, Placebo, Standard of Care Antiemetic Therapies, Background Chemotherapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Greenbrae, California • Irvine, California • Los Alamitos, California + 17 more
- Conditions
- Von Willebrand Disease, Type 3
- Interventions
- Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more
- Conditions
- Glioblastoma (GBM)
- Interventions
- DOC1021, Tumor resection, Temodar (Temozolomide), SOC cranial radiation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Diakonos Oncology Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Duarte, California • Newport Beach, California + 14 more
- Conditions
- Acute Heart Failure
- Interventions
- Short Stay Unit, Standard of Care
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Detroit, Michigan + 8 more
- Conditions
- Venous Insufficiency, Venous Reflux, Lower Extremity Ulcer
- Interventions
- MIST Therapy
- Device
- Lead sponsor
- Celleration, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Weymouth, Massachusetts
- Conditions
- Pulmonary Aspergillosis
- Interventions
- Opelconazole, Standard of Care
- Drug
- Lead sponsor
- Pulmocide Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
- Conditions
- Diabetic Foot Ulcer, Surgical Wound
- Interventions
- Natrox® Oxygen Wound Therapy
- Device
- Lead sponsor
- Inotec AMD Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Miami, Florida • Miami Lakes, Florida + 15 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- Weight loss SOC Treatment with second generation anti-diabetic medications
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Melanoma
- Interventions
- Non-Interventional
- Other
- Lead sponsor
- AIQ Solutions
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Madison, Wisconsin
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 23
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 19 more
- Conditions
- HIV Infections
- Interventions
- TERA Intervention (TERA), Standard of Care (SOC)
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 13 Years to 24 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
- Conditions
- Asthma
- Interventions
- Procedure: Investigational Procedures
- Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 63
- States / cities
- Bessemer, Alabama • Chandler, Arizona • Mesa, Arizona + 49 more